Tebentafusp in first-line melanoma trials: An outperforming outlier
Uveal melanoma is distinct from other melanomas. In the advanced and metastatic stages, little to no improvement have been seen over time. Tebentafusp is a novel mechanism of action bispecific gp100 peptide-HLA-directed CD3 T-cell engager fusion protein (“-fusp”). Tebentafusp was granted full approv...
| Huvudupphovsmän: | , |
|---|---|
| Materialtyp: | Artikel |
| Språk: | English |
| Publicerad: |
Elsevier
2022-06-01
|
| Serie: | Translational Oncology |
| Länkar: | http://www.sciencedirect.com/science/article/pii/S1936523322000705 |